

## DAFTAR PUSTAKA

1. Chen W, Yang A, Zhang N, You H. Liver fibrosis. *Sinusoidal Cells Liver Dis Role their Pathophysiol Diagnosis, Treat.* 2024;115(2):293-316. doi:10.1016/B978-0-323-95262-0.00014-0
2. Khanam A, Saleeb PG, Kottlilil S. Pathophysiology and treatment options for hepatic fibrosis: Can it be completely cured? *Cells.* 2021;10(5). doi:10.3390/cells10051097
3. Elpek GÖ. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. *World J Gastroenterol.* 2014;20(23):7260-7276. doi:10.3748/wjg.v20.i23.7260
4. Pierantonelli I, Svegliati-Baroni G. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression from NAFLD to NASH. *Transplantation.* 2019;103(1):E1-E13. doi:10.1097/TP.0000000000002480
5. Nah EH, Cho S, Kim S, Chu J, Kwon E, Cho HI. Prevalence of liver fibrosis and associated risk factors in the Korean general population: A retrospective cross-sectional study. *BMJ Open.* 2021;11(3):1-10. doi:10.1136/bmjopen-2020-046529
6. Hong S, Hao Y, Sun L, et al. Prevalence and risk factors of significant fibrosis in chronic hepatitis B patients with concurrent metabolic dysfunction-associated steatotic liver disease. *Ann Hepatol.* 2025;30(2). doi:10.1016/j.aohep.2024.101589
7. Gofton C, Upendran Y, Zheng MH, George J. MAFLD: How is it different from NAFLD? *Clin Mol Hepatol.* 2023;29:S17-S31. doi:10.3350/cmh.2022.0367
8. Fouad Y. Metabolic-associated fatty liver disease: New nomenclature and approach with hot debate. *World J Hepatol.* 2023;15(2):123-128. doi:10.4254/wjh.v15.i2.123
9. Sangro P, de la Torre Aláez M, Sangro B, D'Avola D. Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment. *J Physiol Biochem.* 2023;79(4):869-879. doi:10.1007/s13105-023-00954-4
10. Pipitone RM, Ciccioli C, Infantino G, et al. MAFLD: a multisystem disease. *Ther Adv Endocrinol Metab.* 2023;14:1-23. doi:10.1177/20420188221145549
11. Sohn W, Kwon HJ, Chang Y, Ryu S, Cho YK. Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease. *Clin Gastroenterol Hepatol.* 2022;20(5):e1135-e1148. doi:10.1016/j.cgh.2021.06.042
12. Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis. *Harrison's Princ Intern Med.* 2018;2(19):2054-2057.
13. Eslam M, Sarin SK, Wong VWS, et al. *The Asian Pacific Association for the Study of the Liver Clinical Practice Guidelines for the Diagnosis and Management of Metabolic Associated Fatty Liver Disease.* Vol 14. Springer India; 2020. doi:10.1007/s12072-020-10004-0



iang SW, Hu AR, et al. Non-invasive diagnosis of non-alcoholic fatty liver current status and future perspective. *Heliyon.* 2024;10(5):e27325. doi:10.1016/j.heliyon.2024.e27325

Kim HJ, Ko HJ, Kim AS, et al. Prediction of cardiovascular risk using nonalcoholic

- fatty liver disease scoring systems. *Healthc.* 2021;9(7):1-12. doi:10.3390/healthcare9070899
16. Paul J. Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult. *Egypt Liver J.* 2020;10(1). doi:10.1186/s43066-020-00043-x
  17. Byrne CD, Targher G. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate? *Diabetologia.* 2016;59(6):1141-1144. doi:10.1007/s00125-016-3910-y
  18. Cornberg M, Sandmann L, Jaroszewicz J, et al. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol.* 2025;83(2):502-583. doi:10.1016/j.jhep.2025.03.018
  19. Terrault NA, Lok ASF, McMahon, B.J., Al. E. Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. *Hepatology.* 2018;67(4):1560-1599. doi:10.1002/hep.29800.Update
  20. Liedtke C, Nevzorova YA, Luedde T, et al. Liver Fibrosis—From Mechanisms of Injury to Modulation of Disease. *Front Med.* 2022;8(January):1-27. doi:10.3389/fmed.2021.814496
  21. Canivet CM, Boursier J. Screening for Liver Fibrosis in the General Population: Where Do We Stand in 2022? *Diagnostics.* 2023;13(1):1-15. doi:10.3390/diagnostics13010091
  22. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD†. *Hepatology.* 2007;45(4). [https://journals.lww.com/hep/fulltext/2007/04000/the\\_naflf\\_fibrosis\\_score\\_\\_a\\_noninvasive\\_system.3.aspx](https://journals.lww.com/hep/fulltext/2007/04000/the_naflf_fibrosis_score__a_noninvasive_system.3.aspx)
  23. Vanwagner LB, Wilcox JE, Colangelo LA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. *Hepatology.* 2015;62(3):773-783. doi:10.1002/hep.27869
  24. Alexander M, Loomis AK, Fairburn-Beech J, et al. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. *BMC Med.* 2018;16(1):1-11. doi:10.1186/s12916-018-1103-x
  25. Shaji N, Singhai A, Joshi R. Assessment of liver fibrosis using non-invasive screening tools in individuals with diabetes mellitus and metabolic syndrome. *J Assoc Physicians India.* 2022;70(4):11-12. doi:10.7759/cureus.22682
  26. Smith AD, Porter K, Elkassem AA, Sanyal R, Lockhart M. Current Imaging Techniques for Noninvasive Staging of Hepatic Fibrosis Andrew. *Am J Radiol.* Published online 2019.
  27. Chowdhury AB, Mehta KJ. Liver biopsy for assessment of chronic liver diseases: a synopsis. *Clin Exp Med.* 2023;23(2):273-285. doi:10.1007/s10238-022-00799-z



Housset C, Gautheron J. Multiple functions of MLKL in liver fibrosis, from to hepatic stellate cell activation. *Theranostics.* 2022;12(13):5820-5823. doi:10.1016/j.thno.2022.07.002

Chen Q. Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Hepatitis. *J Clin Transl Hepatol.* 2022;10(1):128-133. doi:10.1016/j.jcthep.2022.01.002

doi:10.14218/JCTH.2021.00200

30. Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. *Nat Rev Immunol.* 2022;22(1):19-32. doi:10.1038/s41577-021-00549-4
31. Magee N, Zou A, Zhang Y. Pathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal Cells. *Biomed Res Int.* 2016;2016. doi:10.1155/2016/5170402
32. Machado M V., Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: Meta-analysis of risk factors and comparison with hepatitis C infected patients. *J Gastroenterol Hepatol.* 2011;26(9):1361-1367. doi:10.1111/j.1440-1746.2011.06801.x
33. Choi HSJ, Brouwer WP, Zanjir WMR, et al. Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B. *Hepatology.* 2020;71(2):539-548. doi:10.1002/hep.30857
34. Chan AWH, Wong GLH, Chan HY, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. *J Gastroenterol Hepatol.* 2017;32(3):667-676. doi:10.1111/jgh.13536
35. Lee Y Bin, Ha Y, Chon YE, et al. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B. *Clin Mol Hepatol.* 2018;25(1):52.
36. Marginean CM, Pircscoveanu D, Cazacu SM, et al. Non-Alcoholic Fatty Liver Disease, Awareness of a Diagnostic Challenge—A Clinician’s Perspective. *Gastroenterol Insights.* 2024;15(4):1028-1053. doi:10.3390/gastroent15040071

